M Pharmaceutical Inc (CSNX:MQ, OTCMKTS:MPHMF) has received an official trademark for Extrinsa from the US patent office.
The treatment is a solution for female sexual dysfunction (FSD).
-
READ - M Pharma calls in drug development adviser to advise on Extrinsa
-
READ - M Pharmaceutical poised for clinical trials as FDA is positive on slimming product plans
Unlike the other two drugs approved by the US FDA, Extrinsa focuses on women with orgasm and arousal difficulties.
It is topical, local and non-systemic, while being non-hormonal and not a central nervous system drug, M Pharma pointed out.
"We are excited to receive this additional USPTO trademark protection for our FSD product. At this critical stage in the development of Extrinsa, it is prudent and necessary to protect not only our technology, but our shareholder's investment dollars as well," said Gary Thompson, president and chief executive of M Pharma.
Last week, the group said it had hired Camargo Pharmaceutical Services to advise on a development strategy for Extrinsa.
Camargo is an expert in liaising with the US Food and Drug Administration (FDA) and in aligning drug development plans with business strategies.
It routinely leads up to six meetings with the FDA per month, has guided more than 200 FDA approvals, and works with product developers from more than 25 countries, M said.
"Our staff at M Pharma is working closely with Camargo Pharmaceutical Services based in Cincinnati, Ohio, to strengthen and expedite the process to bring Extrinsa to market, benefiting millions of women suffering from female sexual dysfunction," added Thompson today.
Shares gained over 13% to $0.0375.